Xiang Xiao, Cao Yaying, Sun Kexin, Song Jing, Tian Yaohua, Yin Qiongzhou, Juan Juan, Hu Yonghua
a Department of Epidemiology and Biostatistics, School of Public Health , Peking University Health Science Center , Beijing , PR China.
Curr Med Res Opin. 2018 Feb;34(2):255-261. doi: 10.1080/03007995.2017.1391760. Epub 2017 Nov 8.
Adherence to oral anticoagulants is crucial for the prevention of ischemic stroke in atrial fibrillation patients; however, evidence of oral-anticoagulant adherence from developing countries is still lacking. This study aimed to evaluate the current situation and predictors of oral-anticoagulant adherence in non-valvular atrial fibrillation (NVAF) patients in China.
Records of NVAF patients were obtained from a regional claims database. Both initiation and adherence to oral anticoagulants were calculated from linked records. Factors of oral-anticoagulant initiation were identified using Cox regression.
Among 33,463 NVAF patients, only 13.9% initialized warfarin treatment after the indexed hospital visit. Stratified by CHADS-VASc scores, 20.9% of patients in the low-risk group were on warfarin, followed by 15.3% and 10.7% from the middle and high-risk groups, respectively. Among patients who initialized warfarin, only 40.4% filled the first repeat prescription within 3 months. Concurrent statin use, hypertension and heart failure were associated with higher warfarin initiation rate. Factors such as age above 75, female sex, manufacture workers, discharge from the primary-care center, antiplatelet use, and diabetes, ischemic and hemorrhagic stroke were associated with lower rate of warfarin initiation. Additionally, initiating warfarin treatment reduced risk of ischemic stroke in middle and high-risk patients.
Oral anticoagulation was significantly under-used in NVAF patients in China. Age, sex, concurrent drug usage, and disease history were associated factors. Improving warfarin adherence was promising to reduce ischemic stroke risk of NVAF patients.
坚持服用口服抗凝药对于预防房颤患者的缺血性卒中至关重要;然而,发展中国家关于口服抗凝药依从性的证据仍然不足。本研究旨在评估中国非瓣膜性房颤(NVAF)患者口服抗凝药依从性的现状及预测因素。
从一个地区性理赔数据库中获取NVAF患者的记录。通过关联记录计算口服抗凝药的起始使用情况和依从性。使用Cox回归确定口服抗凝药起始使用的因素。
在33463例NVAF患者中,仅13.9%在索引医院就诊后开始使用华法林治疗。按CHADS-VASc评分分层,低风险组中20.9%的患者使用华法林,中风险组和高风险组分别为15.3%和10.7%。在开始使用华法林的患者中,只有40.4%在3个月内开具了第一张重复处方。同时使用他汀类药物、高血压和心力衰竭与较高的华法林起始使用率相关。年龄在75岁以上、女性、制造业工人、从基层医疗中心出院、使用抗血小板药物以及糖尿病、缺血性和出血性卒中与较低的华法林起始使用率相关。此外,开始使用华法林治疗可降低中高风险患者缺血性卒中的风险。
中国NVAF患者口服抗凝药的使用明显不足。年龄、性别、同时使用的药物以及疾病史是相关因素。提高华法林依从性有望降低NVAF患者缺血性卒中的风险。